金吾财讯 | 国信证券发研报指，远大医药(00512)公告：1)创新药物STC3141在中国开展的用于治疗脓毒症的II期临床研究成功达到临床终点；2)创新RDC产品TLX591加入国际多中心III期临床试验的申请已获国家药监局受理；3)用于诊断肝细胞癌的创新RDCGPN02006在中国开展的研究者发起的临床研究(IIT临床研究)结果将于2025年北美核医学与分子影像学会(SNMMI)年会中公布；4)成都温江核药全球研发及生产基地将在2025年6月正式投入运营。该机构表示，1)脓毒症的精准治疗是明确的未满足的临床需求，STC3141是全球首个以重新构建免疫稳态为核心的脓毒症治疗方案，中国II期临床研究成功达到临床终点，有望推动脓毒症治疗迈入新纪元；2)核药领域已出现“重磅炸弹”级别药物，国际MNC纷纷入局核药，远大医药RDC临床进展不断，产品管线储备丰富，有望迎来价值重估。该机构续指，远大医药自2015年以来加速创新转型，期待钇[90Y]微球注射液持续销售放量；RDC研发进度位于行业前列，即将进入收获期；STC3141有望推动脓毒症治疗迈入新纪元。维持盈利预测，预计2025-27年归母净利润22.18/24.65/27.97亿港币，同比增长-10.1%/11.1%/13.4%，当前股价对应PE为14.8/13.3/11.7X。各业务板块合计估值371-412亿港币，对应10.45-11.60港币，维持“优于大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.